Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant to treat glaucoma.
Avisi is developing a portfolio of medical devices for eye care.
- Commercializing a patented metamaterial platform technology
- First product is VisiPlate, a minimally invasive glaucoma shunt
- Experienced, expert team with numerous awards
- $10M+ raised to date from VC investors and multiple NSF Grants
- Current fundraising round for US trial and market clearance
VisiPlate is a nanotechnology-enabled aqueous shunt implanted in the subconjunctival space of the eye with the following key characteristics.
- Ultrathin profile (~6 μm metamaterial): eliminates mechanical stress with flexible, low‑lying material.
- Network of microchannels: provides redundant, multiple pathways for controlled outflow.
- Nonfibrotic material: alumina and Parylene‑C composition avoid failure from scarring.